Sort   by:  
 Page size 
ProteomicsFasting boosts breast cancer therapy via glucocorticoid activation.
The vast majority of all breast cancers are driven by oestrogen receptor alpha (ERα) activation, and endocrine therapy represents the mainstay treatment for these patients. However, resistance is common and tumours progress despite years of systemic endocrine suppression. Periodic fasting enhances t...
ORGANISM(S): Homo sapiens (Human) 
2025-10-14 | PXD049477 | Pride
Glucocorticoid receptor Endocrine therapy Lc-msms Fasting Human Breast cancer 
ProteomicsTRIM24 as therapeutic target in endocrine treatment resistant breast cancer
While ERα+ breast cancer treatment is considered effective, resistance to endocrine therapy is common. Since in therapy-resistance tumors, ERα is still the main driver, alternative therapeutic strategies are needed to disrupt ERα transcriptional activity. In this work, we describe TRIM24 as a key pl...
ORGANISM(S): Homo sapiens (Human) 
2025-08-01 | PXD046736 | Pride
Erα Protac Therapy resistant breast cancer 
ProteomicsPAXIP1 and STAG2 converge to maintain 3D genome archi-tecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription
How steroid hormone receptors (SHRs) orchestrate transcriptional activity remains only partly understood. Upon activation, SHRs bind the genome and recruit their co-regulators, crucial to induce gene expression. However, it remains unknown which components of the SHR-recruited coregulator complex ar...
ORGANISM(S): Homo sapiens (Human) 
2023-10-24 | PXD038902 | Pride
Lc-msms  paxip1  stag2  rime glucocorticoid receptor 
ProteomicsDrug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence
In prostate cancer, androgen receptor (AR)-targeting agents are very effective in various stages of the disease. However, therapy resistance inevitably occurs and little is known about how tumor cells adapt to bypass AR suppression. Here, we performed integrative multi-omics analyses on tissues isol...
ORGANISM(S): Homo sapiens (Human) 
2022-10-14 | PXD032041 | Pride
Foxa1 Prostate cancer Androgen receptor(ar) Enzalutamide Lc-msms Arntl 
UnknownNeoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.
Not available
S-EPMC5085127 | biostudies-literature
UnknownThe BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
Not available
S-EPMC5574249 | biostudies-literature
UnknownBRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
Not available
S-EPMC5528786 | biostudies-literature
UnknownAssessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.
Not available
S-EPMC6279322 | biostudies-literature
UnknownDNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
Not available
S-EPMC5572474 | biostudies-literature
UnknownRobust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.
Not available
S-EPMC5528812 | biostudies-literature
Sort   by:  
 Page size